An open-label, Phase I dose escalation study of theliatinib monotherapy in wild-type EGFR NSCLC

Trial Profile

An open-label, Phase I dose escalation study of theliatinib monotherapy in wild-type EGFR NSCLC

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Sep 2016

At a glance

  • Drugs Theliatinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Sep 2016 New trial record
    • 02 Aug 2016 According to a Chi-Med media release, this study has completed eight once-daily dose cohorts. The maximum tolerated dose has not yet been reached and dose escalation is continuing. company expects to conclude Phase II dose from this trial by the end of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top